# Tirzepatide: The Dual GIP/GLP-1 Agonist That Beat Semaglutide Head-to-Head > Tirzepatide is FDA-approved for type 2 diabetes, obesity, and sleep apnea. SURPASS-2: -2.30%-pt HbA1c vs -1.86 with semaglutide. SURMOUNT-1: -20.9% body weight. Cited. SURPASS-2: superior HbA1c reduction vs semaglutide across all three doses. SURMOUNT-5: -20.2% body weight vs -13.7%. One drug, two receptors, one consistent result. ## The short version Tirzepatide is a once-weekly injection approved by the FDA for type 2 diabetes (2022), obesity (2023), and obstructive sleep apnea (2024). It is the first drug to work on two gut hormone signals at the same time — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both of these are natural signals your gut sends after a meal to tell your pancreas to release insulin. By hitting both signals with a single molecule, tirzepatide produces larger reductions in blood sugar and body weight than older drugs that only hit GLP-1 alone. In the biggest obesity trial to date (SURMOUNT-1, 2,539 people), participants at the highest dose lost an average of 20.9% of their body weight over 72 weeks [4]. In a head-to-head comparison against semaglutide in people without diabetes (SURMOUNT-5), tirzepatide produced -20.2% weight loss versus -13.7% [5]. The most common side effects are nausea, constipation, and diarrhea — mostly during dose escalation. What people report — including the downsides — is covered on [the effects page](/effects). ## Tirzepatide: what the trial record actually shows Tirzepatide is a 39-amino-acid synthetic peptide engineered on the GIP backbone, modified with a C20 fatty-diacid arm that confers high albumin affinity and a ~5-day elimination half-life — the property that makes once-weekly dosing viable [1]. The molecule's defining feature is dual agonism. It activates both the GIP receptor and the GLP-1 receptor, but it does not hit them equally: in vitro work established it engages the GIP receptor more fully than the GLP-1 receptor — an 'imbalanced' dual agonist — and its GLP-1 receptor signalling is biased toward cAMP generation over beta-arrestin recruitment, a property that may enhance insulin secretion [2]. The SURPASS trial programme tested Tirzepatide in type 2 diabetes across five large randomised trials. SURPASS-1 (monotherapy vs placebo) showed dose-dependent HbA1c and weight reduction [8]. SURPASS-2 (vs semaglutide 1 mg, n=1,879, 40 weeks) produced HbA1c reductions of -2.01, -2.24, and -2.30 percentage points at 5, 10, and 15 mg respectively, versus -1.86 points with semaglutide — tirzepatide was noninferior and superior at all three doses [3]. Body weight differences were -1.9, -3.6, and -5.5 kg in favour of tirzepatide [3]. [Tirzepatide research](/research) covers the full SURPASS and SURMOUNT record. The SURMOUNT programme tested Tirzepatide in obesity. SURMOUNT-1 (n=2,539, 72 weeks, non-diabetic participants) found mean weight changes of -15.0%, -19.5%, and -20.9% at 5, 10, and 15 mg versus -3.1% with placebo [4]. SURMOUNT-5, a head-to-head against semaglutide in 751 non-diabetic adults, found -20.2% with tirzepatide versus -13.7% with semaglutide — tirzepatide superior across all weight-loss thresholds [5]. Beyond glycaemia and obesity, readouts have followed: SUMMIT (heart failure with preserved ejection fraction), SURMOUNT-OSA (obstructive sleep apnea), and SYNERGY-NASH (metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease). ## Tirzepatide vs semaglutide Two separate head-to-head trials have now compared [tirzepatide injection](/injection) with semaglutide directly. SURPASS-2 (type 2 diabetes, n=1,879, 40 weeks): tirzepatide 5/10/15 mg versus semaglutide 1 mg. HbA1c reduction -2.01/-2.24/-2.30 vs -1.86 percentage points. Weight change treatment differences -1.9/-3.6/-5.5 kg in favour of tirzepatide at each dose. Tirzepatide was noninferior and superior at all three doses tested [3]. SURMOUNT-5 (obesity without type 2 diabetes, n=751, 72 weeks): maximum tolerated dose of tirzepatide (10 or 15 mg) versus maximum tolerated dose of semaglutide (1.7 or 2.4 mg). Least-squares mean weight change: -20.2% vs -13.7% (P<0.001). Tirzepatide also produced greater reductions in waist circumference and higher proportions reaching ≥10/15/20/25% weight loss thresholds [5]. Note: the comparison in SURPASS-2 was against the 1 mg dose of semaglutide, not the higher obesity doses. SURMOUNT-5 used maximum tolerated doses of both agents. ## Tirzepatide weight loss The SURMOUNT-1 weight-loss finding is the largest yet recorded in a placebo-controlled obesity trial. At 15 mg, 63% of participants lost ≥20% of their body weight over 72 weeks, compared with 1.3% on placebo [4]. The trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a weight-related complication) and without type 2 diabetes. In SURMOUNT-5, the head-to-head against semaglutide, tirzepatide produced -20.2% weight loss versus -13.7% [5]. Both trials used a 20-week escalation schedule before reaching maintenance doses. Tirzepatide results in SURPASS-2 also included weight loss as a secondary endpoint, with treatment differences of up to -5.5 kg at the highest dose versus semaglutide 1 mg [3]. A SURMOUNT-1 body composition substudy found that approximately 25% of weight lost was lean mass, with the remaining ~75% fat mass [12]. The clinical significance of this lean-mass loss is under active investigation. ## Tirzepatide reviews Across the SURPASS and SURMOUNT programmes, tirzepatide produced the most consistent and largest glycaemic and weight outcomes of any dual incretin agent tested to date [7]. The StatPearls clinical reference confirms it as an FDA-approved dual GLP-1/GIP receptor agonist and summarises the trial record [7]. In structured patient interview studies, 79-91% of SURMOUNT trial participants described reduced appetite as a top benefit, and roughly 62-79% reported increased energy over the treatment course. Approximately 47-55% described improved mood and self-confidence. These are patient-reported experiences, not controlled trial endpoints — see [Tirzepatide effects](/effects) for the full community-signal picture. Tirzepatide results in randomised trials are replicated across multiple independent comparisons — SURPASS-1 through -5 and SURMOUNT-1 and -5 — with consistent dose-response patterns at 5, 10, and 15 mg. ## Tirzepatide peptide Tirzepatide is a synthetic 39-amino-acid peptide built on the native GIP sequence. Its molecular formula is C225H348N48O68, molecular weight 4813.53 Da, CAS number 2023788-19-2, ATC code A10BX16. The fatty-diacid modification — a C20 eicosanedioic acid attached via a glutamic acid linker and two aminoethoxyethoxyacetic acid units to a lysine side chain — confers high albumin affinity, yielding the ~5-day elimination half-life that supports once-weekly subcutaneous administration [1]. The 'incretin effect' it amplifies describes the phenomenon by which gut hormones (GIP and GLP-1) released after eating enhance insulin secretion from the pancreas in a glucose-dependent manner — meaning the effect is strongest when blood glucose is high and diminishes as it normalises, which is why tirzepatide carries a low intrinsic hypoglycaemia risk on its own [7]. The [tirzepatide injection](/injection) page covers subcutaneous administration and the dose-escalation schedule documented in the label and clinical trials. ## Tirzepatide cost Tirzepatide is a prescription medication dispensed through licensed pharmacies and healthcare systems. List pricing for branded formulations is set by the manufacturer and subject to change; actual patient cost depends on insurance coverage, formulary tier, manufacturer assistance programmes, and geography. This site covers the research record — pricing, sourcing, and access are outside the scope of the published efficacy and safety literature. This site does not sell tirzepatide and does not link to any vendor, pharmacy, or compounding source. --- The trial record, read straight — two receptors, one cited page, no white coat and nothing prescribed.